Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
about
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participateTarget of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsLymphatic disorders after renal transplantation: new insights for an old complicationSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsDo wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsCurrent state of renal transplant immunosuppression: Present and futureReviewing 15 years of experience with sirolimusEverolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the ratMycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolismAccelerated wound healing by mTOR activation in genetically defined mouse models.Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients--an analysis of USRDS data.Dyslipidemia during sirolimus therapy in patients after liver transplantation.Use of sirolimus in kidney transplantation.Critical care aspects of lung transplantation.Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.The pros and the cons of mTOR inhibitors in kidney transplantation.A comprehensive review of immunosuppression used for liver transplantation.Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Recent advances in immunosuppressive therapy for renal transplantation.mTOR inhibitors: an overview.Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases.Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia.Immunosuppressive therapy and post-transplantation diarrhea.Sirolimus: a comprehensive review.Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.Strategies to reduce toxicities and improve outcomes in renal transplant recipients.New developments in immunosuppressive therapy in renal transplantation.Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisA randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptionsCalcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.What's in the pipeline? New immunosuppressive drugs in transplantation.Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway.Functional modulation of dendritic cells to suppress adaptive immune responses.FTY720: A new kid on the block for transplant immunosuppression.Evolution of endpoints for renal transplant outcome.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationSirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients.Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
P2860
Q24242288-B6CB4227-34A6-4BF8-9548-9B6C1FD916C8Q24246340-99E6B5DA-5CA9-4D59-B1FB-F21C107EDD35Q26785848-EB6D37E1-4EF3-45BE-AB4B-ED957D2DFB0FQ26823023-25D7797F-95AC-405C-B659-E5B22B1918C2Q26823281-1CC4E0C7-07E6-44CE-A2ED-C27DA2338127Q26829789-9513DCD9-5E43-4FDB-855F-2A285142EF10Q28080955-0E349112-2562-4540-8A5E-DF76094E66A7Q28484671-C97208A6-53C8-484B-958E-AE81E804C909Q28539334-D674A10D-9DF5-4A89-8BE4-D5F95853F0E8Q30389607-F24B9277-215E-45C2-9747-A41F4AB39A31Q31095760-AF72FCFB-F9FC-405E-8CFC-66FAF0648D89Q33208512-FDAA61A6-0E7D-4EEB-ADAE-09EF055B129CQ33337338-B613E045-913B-422D-BB39-BD003137FB73Q33360317-EEF8B57C-EDD9-4AE3-8020-34FE0B9734ACQ33393707-EB3B2745-5555-48F4-9AF0-08F1F6F9F5BFQ33412367-CBD9452C-9B85-4902-9753-06E52F0AD8F1Q33602527-7DB749B5-9FB5-4945-A975-351D7E6D5AB2Q33848529-5750A10F-F83C-4990-80FE-829C798AED58Q34291820-FA43691E-EDE9-4118-95B9-27C7E7EB0F06Q34302240-96C606CA-6297-4599-854D-6127E5132EA0Q34358191-CE1048B4-B5C4-4A5E-AD56-A9F05385353BQ34362275-3C94D310-A5DA-41C6-8364-380FB41FB3E2Q34485488-9A3C49A8-01DC-4014-98E8-4CF5611DF685Q34515537-8F428818-9939-4FE6-A6F4-10B3421E7B65Q34520835-92FD6142-BA99-4AE1-898C-ACA06118580EQ34546358-E372E6E0-AABE-4E82-BC0D-DEF0B1FDD191Q34566924-80D210B2-C69C-4539-AF86-E58ED311E7E4Q34701373-50AFE620-E216-4244-94A6-300995ED3FAFQ34778631-B44285DB-6D3B-4723-8AFA-BADA3BB0D7ADQ34805919-1687CD5A-6300-4817-866A-483378EA53F7Q34814081-240FCB20-ADBE-4405-BE5A-A8DBBF9C8853Q35015840-A356BEB0-4B6D-43FE-96B5-B7148E6F4D19Q35025829-972510F2-D40C-4361-8380-299E2A4EE5E9Q35071033-BFDE767F-42A8-42D1-A5E5-30A8FCD04382Q35093120-3DCAD905-D4C9-44C9-9DA4-8F0E2A969A76Q35164822-2D7492B0-84C6-47EA-8206-6817453343AEQ35177426-8DE42241-7BC2-4D8D-87FB-D8A04D0B8E15Q35184589-42E6E769-F773-4A05-ADC4-281105F32653Q35803895-28421772-CB78-4D3C-8231-C272CF4B843DQ35819373-773A993E-0717-4BB0-9AEE-F6955F1AB90D
P2860
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
description
article publié dans la revue scientifique The Lancet
@fr
im Juli 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2000
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Efficacy of sirolimus compared ...... a randomised multicentre study
@en
Efficacy of sirolimus compared ...... a randomised multicentre study
@nl
type
label
Efficacy of sirolimus compared ...... a randomised multicentre study
@en
Efficacy of sirolimus compared ...... a randomised multicentre study
@nl
prefLabel
Efficacy of sirolimus compared ...... a randomised multicentre study
@en
Efficacy of sirolimus compared ...... a randomised multicentre study
@nl
P1433
P1476
Efficacy of sirolimus compared ...... y. The Rapamune US Study Group
@en
P2093
P304
P356
10.1016/S0140-6736(00)02480-6
P407
P577
2000-07-01T00:00:00Z